SifalimumabSifalimumab
MedChemExpress (MCE)
HY-P99219
1006877-41-3
MEDI-545
MDX 1103
98.55%
Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping with dry ice.
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research.
Sifalimumab (3-36 μg/well
72 h) attenuates lymphocyte cytotoxicity co-cultured with U-87MG[2].
Sifalimumab (subcutaneous injection
30 mg/kg and 3 μg/g) treatment shows therapeutic effect and attenuates the lymphocyte infiltration[2].
Human
Human IgG1 kappa
Human IgG1 kappa, Isotype Control
| | | |
| | | | | |
[1]. Merrill JT, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov
70(11):1905-13. [Content Brief]
[2]. La Maestra S, et al. Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation. Drug Deliv Transl Res. 2018 Oct
8(5):1345-1354. [Content Brief]